Calidi Biotherapeutics (CLDI) vs Liminatus Pharma (LIMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liminatus Pharma is the larger company by market cap ($5.0 million vs $3.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | LIMN |
|---|---|---|
| Share price | $1.04 | $3.69 |
| Market cap | $3.82M | $4.96M |
| 1-day change | +2.97% | -4.65% |
| EPS (TTM) | $-36.47 | $-23.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $141.50 |
| 52-week low | $0.986 | $3.29 |
| Distance from 52-week high | -96.26% | -97.39% |
| Average volume | 255.53K | 453.28K |
| Shares outstanding | 3.68M | 1.34M |
| Employees | 29 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 29 employees
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
CLDI vs LIMN FAQ
Which is bigger, Calidi Biotherapeutics or Liminatus Pharma?
Liminatus Pharma (LIMN) is larger, with a market capitalization of $4.96M compared with $3.82M for Calidi Biotherapeutics (CLDI).
Are Calidi Biotherapeutics and Liminatus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.